Eli Lilly’s new CEO is ready to start partnering on R&D
During John Lechleiter’s rule as CEO of Eli Lilly, the company’s emphasis was always on its own internal pipeline. Lilly did a few pacts, almost solely with big players on deals that included a pricey late-stage agreement to partner with Pfizer on tanezumab for pain, but it largely stayed away from the main action.
That might be about to change.
“I wouldn’t look for a dramatic change, but maybe (expect) an acceleration of interest in partnering externally,” David Ricks told Reuters. “There are a lot of good ideas out there.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
